RenovoRx, Inc. Executive Chairman and CMO Ramtin Agah filed a Form 4 on November 17, 2026, disclosing an open market purchase of 50,000 shares of common stock on November 16, 2026.
Key Highlights
- Transaction date: November 16, 2026, with 50,000 shares of common stock acquired.
- Weighted average price: $0.9297 per share, reflecting multiple transactions ranging from $0.925 to $0.9299 per share.
- Resulting ownership: Ramtin Agah directly holds 848,460 shares of common stock following the transaction.
- Transaction type: Open market purchase, coded "P" in the filing.
- Roles: The reporting person is identified as both a Director and an Officer, holding the title of Executive Chairman and CMO.
Ramtin Agah's Open Market Purchase of RenovoRx Common Stock
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 17, 2026, Ramtin Agah, Executive Chairman and Chief Medical Officer of RenovoRx, Inc. (NASDAQ:RNXT), acquired 50,000 shares of the company's common stock on November 16, 2026. The filing describes the transaction as open market purchases of the issuer's securities.
The filing states that the reported price of $0.9297 is a weighted average, noting that "the securities were purchased in multiple transactions at per share prices ranging from $0.925 to $0.9299." Following this acquisition, Agah's direct beneficial ownership of RenovoRx common stock stood at 848,460 shares, as reported in Table I of the filing. No derivative securities were reported in Table II.
The Form 4 was filed by one reporting person and covers non-derivative securities only. Agah signed the filing on November 17, 2026. No amendment date was indicated, and the box for Rule 10b5-1(c) plan transactions was not checked.
What Was Disclosed
Ramtin Agah, Executive Chairman and CMO of RenovoRx, Inc., reported purchasing 50,000 shares of common stock at a weighted average price of $0.9297 on November 16, 2026, bringing his direct beneficial ownership to 848,460 shares.




Please wait processing your request...